UY37809A - Pirrolopirimidina y derivados de pirrolopirimidina - Google Patents
Pirrolopirimidina y derivados de pirrolopirimidinaInfo
- Publication number
- UY37809A UY37809A UY0001037809A UY37809A UY37809A UY 37809 A UY37809 A UY 37809A UY 0001037809 A UY0001037809 A UY 0001037809A UY 37809 A UY37809 A UY 37809A UY 37809 A UY37809 A UY 37809A
- Authority
- UY
- Uruguay
- Prior art keywords
- diseases
- pirrolopirimidina
- compounds
- prophylaxis
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención está relacionada con compuestos de pirrolopirimidina de acuerdo con la Fórmula I y su uso en la profilaxis y/o el tratamiento del dolor, afecciones inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, enfermedades neurológicas, complicaciones de la diabetes tipo I, cáncer y/o enfermedades fibróticas. En un aspecto particular, los compuestos de la presente son inhibidores de ASK (quinasa reguladora de la señal de apoptosis). También proporciona métodos para la producción de un compuesto de la invención, composiciones farmacéuticas que comprenden un compuesto de la invención, y el uso de los compuestos en la profilaxis y/o tratamiento de distintas enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1711234.3A GB201711234D0 (en) | 2017-07-12 | 2017-07-12 | Pyrrolopyrimidine and pyrrolopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37809A true UY37809A (es) | 2019-02-28 |
Family
ID=59676761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037809A UY37809A (es) | 2017-07-12 | 2018-07-12 | Pirrolopirimidina y derivados de pirrolopirimidina |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11136325B2 (es) |
| EP (1) | EP3652173A1 (es) |
| JP (1) | JP7198263B2 (es) |
| KR (1) | KR20200028436A (es) |
| CN (1) | CN111094283A (es) |
| AR (1) | AR112333A1 (es) |
| AU (1) | AU2018300218B2 (es) |
| BR (1) | BR112020000578A2 (es) |
| CA (1) | CA3069358A1 (es) |
| CO (1) | CO2020001346A2 (es) |
| GB (1) | GB201711234D0 (es) |
| IL (1) | IL271910B2 (es) |
| MX (1) | MX2020000005A (es) |
| PH (1) | PH12019502823A1 (es) |
| SG (1) | SG11202000168UA (es) |
| TW (1) | TWI794253B (es) |
| UY (1) | UY37809A (es) |
| WO (1) | WO2019012284A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
| CN111303155A (zh) * | 2020-03-13 | 2020-06-19 | 深圳大学 | 靶向pak1抑制剂及其在抗肿瘤治疗药物中的应用 |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| KR102635126B1 (ko) * | 2021-05-27 | 2024-02-13 | 한국과학기술연구원 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도 |
| TW202310836A (zh) * | 2021-07-28 | 2023-03-16 | 美商埃皮里姆生物股份有限公司 | 吡咯并[2,3-b]吡啶PGDH抑制劑及製備與使用方法 |
| WO2023014049A1 (ko) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784878B2 (en) | 1999-12-02 | 2006-07-13 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof |
| TW200306191A (en) * | 2002-02-22 | 2003-11-16 | Teijin Ltd | Pyrrolopyrimidine derivatives |
| AU2003284597A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Apoptosis-associated protein and use thereof |
| WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
| EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| KR20100075881A (ko) | 2007-08-31 | 2010-07-05 | 메르크 세로노 에스. 에이. | 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도 |
| JP5432982B2 (ja) | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ１阻害剤 |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
| GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
-
2017
- 2017-07-12 GB GBGB1711234.3A patent/GB201711234D0/en not_active Ceased
-
2018
- 2018-07-12 MX MX2020000005A patent/MX2020000005A/es unknown
- 2018-07-12 CN CN201880045891.9A patent/CN111094283A/zh active Pending
- 2018-07-12 UY UY0001037809A patent/UY37809A/es not_active Application Discontinuation
- 2018-07-12 JP JP2020501447A patent/JP7198263B2/ja active Active
- 2018-07-12 SG SG11202000168UA patent/SG11202000168UA/en unknown
- 2018-07-12 WO PCT/GB2018/051983 patent/WO2019012284A1/en unknown
- 2018-07-12 BR BR112020000578-9A patent/BR112020000578A2/pt unknown
- 2018-07-12 AU AU2018300218A patent/AU2018300218B2/en not_active Ceased
- 2018-07-12 KR KR1020207004013A patent/KR20200028436A/ko not_active Application Discontinuation
- 2018-07-12 CA CA3069358A patent/CA3069358A1/en active Pending
- 2018-07-12 EP EP18745683.5A patent/EP3652173A1/en active Pending
- 2018-07-12 AR ARP180101945 patent/AR112333A1/es unknown
- 2018-07-12 US US16/632,202 patent/US11136325B2/en active Active
- 2018-07-12 TW TW107124084A patent/TWI794253B/zh active
-
2019
- 2019-12-13 PH PH12019502823A patent/PH12019502823A1/en unknown
-
2020
- 2020-01-08 IL IL271910A patent/IL271910B2/en unknown
- 2020-02-06 CO CONC2020/0001346A patent/CO2020001346A2/es unknown
-
2021
- 2021-09-03 US US17/466,230 patent/US20220169653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020001346A2 (es) | 2020-05-29 |
| AR112333A1 (es) | 2019-10-16 |
| KR20200028436A (ko) | 2020-03-16 |
| GB201711234D0 (en) | 2017-08-23 |
| IL271910B2 (en) | 2023-07-01 |
| MX2020000005A (es) | 2020-08-06 |
| AU2018300218A1 (en) | 2020-02-27 |
| WO2019012284A1 (en) | 2019-01-17 |
| JP2020530833A (ja) | 2020-10-29 |
| JP7198263B2 (ja) | 2022-12-28 |
| CA3069358A1 (en) | 2019-01-17 |
| US11136325B2 (en) | 2021-10-05 |
| PH12019502823A1 (en) | 2020-10-26 |
| CN111094283A (zh) | 2020-05-01 |
| RU2020106289A (ru) | 2021-08-12 |
| SG11202000168UA (en) | 2020-02-27 |
| TWI794253B (zh) | 2023-03-01 |
| US20200165259A1 (en) | 2020-05-28 |
| IL271910B1 (en) | 2023-03-01 |
| AU2018300218B2 (en) | 2021-12-16 |
| EP3652173A1 (en) | 2020-05-20 |
| RU2020106289A3 (es) | 2021-11-10 |
| IL271910A (en) | 2020-02-27 |
| BR112020000578A2 (pt) | 2020-07-14 |
| TW201908312A (zh) | 2019-03-01 |
| US20220169653A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37809A (es) | Pirrolopirimidina y derivados de pirrolopirimidina | |
| ECSP20060827A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| EA202090419A1 (ru) | Селективные ингибиторы инфламмасомы nlrp3 | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CO2017000912A2 (es) | Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| GEP20217316B (en) | Aromatic sulfonamide derivatives | |
| ECSP17006821A (es) | Inhibidores de la desmetilasa-1 específica de la lisina | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| ECSP17046848A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis | |
| CL2019002079A1 (es) | Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611) | |
| UY37225A (es) | Inhibidores del potenciador del homólogo zeste 2 campo de la invención | |
| ECSP17023551A (es) | Inhibidores de histona desmetilasa | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| EA201790276A1 (ru) | Новые имидазопиридазиновые соединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20231110 |